Amgen Inc.

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results conference call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q&A session. To ask a question, please press star then the number one on your telephone keypad. To withdraw your question, please press star 1 again. I would now like to introduce Justin Clay, Vice President of Investor Relations. Mr. Clay, you may now begin.

Thank you, Julianne. Good afternoon, everyone, and welcome to our third quarter 2024 earnings call. Bob Bradway will lead the call and be followed by a broader review of our performance by Myrto Gordon, Vikram Karnani, Jay Bradner, and Peter Griffith. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our State Harbor Statement, and please note that actual results can vary materially. Over to you, Bob.

Thank you for joining us today. Our performance this quarter reflects the strength of our business across our core therapeutic areas and geographies. Our in-market medicines performed well in the quarter, with third quarter revenues up 23% to $8.5 billion, and 10 of our products delivering double-digit or better sales growth. We're also rapidly advancing our pipeline with a significant number of potentially first-in-class or best-in-class medicines positioning us for long-term growth. Let me address Meritide directly. Our ongoing phase two study is progressing well, and we look forward to sharing results later this year. We're well advanced in preparing to launch a broad phase three program for Meritide, including obesity, obesity-related conditions, and type two diabetes. You may have noted that we recently initiated a phase two study in patients with type two diabetes. As we shared after the interim analysis, we're confident that Meritide's differentiated profile will address important unmet medical needs across a number of diseases, including type 2 diabetes. Beyond obesity, we have momentum across each of our therapeutic areas, and I'll start with oncology. In the third quarter, we saw strong in-market performance with 17% sales growth across the innovative oncology portfolio. And several products experienced double-digit growth, including Blinsito, which, of course, is our first bispecific T-cell engager or bite, which is now established as the standard of care in B-cell acute lymphoblastic leukemia. The launch of our next bite, Imdeltra, is also progressing well with strong clinical conviction and three Phase III studies underway in small-cell lung cancer. In further demonstrating the strength and promise of this platform in solid tumors, we're pleased to announce today that we will advance valuridamig into Phase III clinical development and advance prostate cancer in the fourth quarter. Let me remind you to also keep an eye out for Phase III bimerituzumab data in gastric cancer, which we should have in the next few months. Our rare disease portfolio delivered $1.2 billion of sales in the quarter, growing 21% year over year, driven by Tepeza, Christexa, Uplizna, and Tavneos. These medicines are highly innovative, are still in the early stages of their life cycles, and have significant upside potential, including expansion into new indications and geographies. For example, Tepeza was recently approved in Japan. Also in rare disease, The PLSNA demonstrated compelling data in generalized myasthenia gravis and was granted breakthrough therapy designation in IgG4-related diseases. We're excited about the promise of inebilizumab in these settings and potentially in other B-cell-mediated autoimmune diseases. In inflammation, TESPIRE continues its strong trajectory with 67% growth year-over-year in the quarter. We're further encouraged by the potential of test spire in COPD and additional indications that we're also actively exploring. And finally, in general medicine, Repatha and Avenity are each delivering strong volume growth again this quarter. These products are pivotal as we continue to serve more patients and meet the growing demand for therapies that address some of the most serious health challenges worldwide, like heart disease and osteoporosis. Looking ahead, we remain confident that Amgen is well-positioned to deliver long-term growth and innovation across each of our therapeutic areas. Our balanced portfolio combined with the strength of our pipeline, we think will continue to drive our business forward. As always, I'd like to thank my colleagues across Amgen for their unwavering commitment to patients. I want to now turn the call over to Murdo.